Search Results - "Fay, Andre P."

Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations by Albiges, Laurence, Hakimi, A Ari, Xie, Wanling, McKay, Rana R, Simantov, Ronit, Lin, Xun, Lee, Jae-Lyun, Rini, Brian I, Srinivas, Sandy, Bjarnason, Georg A, Ernst, Scott, Wood, Lori A, Vaishamayan, Ulka N, Rha, Sun-Young, Agarwal, Neeraj, Yuasa, Takeshi, Pal, Sumanta K, Bamias, Aristotelis, Zabor, Emily C, Skanderup, Anders J, Furberg, Helena, Fay, Andre P, de Velasco, Guillermo, Preston, Mark A, Wilson, Kathryn M, Cho, Eunyoung, McDermott, David F, Signoretti, Sabina, Heng, Daniel Y C, Choueiri, Toni K

“…Obesity is an established risk factor for clear cell renal cell carcinoma (RCC); however, some reports suggest that RCC developing in obese patients may be…”
Get full text

Intercomparison of radiosensitization induced by gold and iron oxide nanoparticles in human glioblastoma cells irradiated by 6 MV photons by Guerra, Danieli B., Oliveira, Elisa M. N., Sonntag, Amanda R., Sbaraine, Patricia, Fay, Andre P., Morrone, Fernanda B., Papaléo, Ricardo M.

“…In this work, an intercomparison of sensitization effects produced by gold (GNP) and dextran-coated iron oxide (SPION-DX) nanoparticles in M059J and U87 human…”
Get full text

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial by Agarwal, Neeraj, Azad, Arun A, Carles, Joan, Fay, Andre P, Matsubara, Nobuaki, Heinrich, Daniel, Szczylik, Cezary, De Giorgi, Ugo, Young Joung, Jae, Fong, Peter C C, Voog, Eric, Jones, Robert J, Shore, Neal D, Dunshee, Curtis, Zschäbitz, Stefanie, Oldenburg, Jan, Lin, Xun, Healy, Cynthia G, Di Santo, Nicola, Zohren, Fabian, Fizazi, Karim

“…Co-inhibition of poly(ADP-ribose) polymerase (PARP) and androgen receptor activity might result in antitumour efficacy irrespective of alterations in DNA…”
Get full text

A Systematic Review and Meta-analysis of Adjuvant and Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma by Leow, Jeffrey J, Martin-Doyle, William, Fay, André P, Choueiri, Toni K, Chang, Steven L, Bellmunt, Joaquim

“…Abstract Context The role of adjuvant chemotherapy (AC) or neoadjuvant chemotherapy (NC) remains poorly defined for the management of upper tract urothelial…”
Get full text

Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma by Kwiatkowski, David J, Choueiri, Toni K, Fay, André P, Rini, Brian I, Thorner, Aaron R, de Velasco, Guillermo, Tyburczy, Magdalena E, Hamieh, Lana, Albiges, Laurence, Agarwal, Neeraj, Ho, Thai H, Song, Jiaxi, Pignon, Jean-Christophe, Barrios, Pablo M, Michaelson, M Dror, Van Allen, Eliezer, Krajewski, Katherine M, Porta, Camillo, Pal, Sumanta, Bellmunt, Joaquim, McDermott, David F, Heng, Daniel Y C, Gray, Kathryn P, Signoretti, Sabina

“…We examined the hypothesis that mutations in mTOR pathway genes are associated with response to rapalogs in metastatic renal cell carcinoma (mRCC). We studied…”
Get full text

Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial by Choueiri, Toni K, Figueroa, David J, Fay, André P, Signoretti, Sabina, Liu, Yuan, Gagnon, Robert, Deen, Keith, Carpenter, Christopher, Benson, Peter, Ho, Thai H, Pandite, Lini, de Souza, Paul, Powles, Thomas, Motzer, Robert J

“…The interaction of programmed death-1 ligand (PD-L1) with its receptor (PD-1) on T cells inactivates antitumor immune responses. PD-L1 expression has been…”
Get full text

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design by Agarwal, Neeraj, Azad, Arun, Shore, Neal D, Carles, Joan, Fay, Andre P, Dunshee, Curtis, Karsh, Lawrence Ivan, Paccagnella, Maria Luisa, Santo, Nicola Di, Elmeliegy, Mohamed, Lin, Xun, Czibere, Akos, Fizazi, Karim

“…PARP inhibitors in combination with androgen receptor-targeted therapy have demonstrated potential in the treatment of metastatic castration-resistant prostate…”
Get full text

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial by Fizazi, Karim, Azad, Arun A., Matsubara, Nobuaki, Carles, Joan, Fay, Andre P., De Giorgi, Ugo, Joung, Jae Young, Fong, Peter C. C., Voog, Eric, Jones, Robert J., Shore, Neal D., Dunshee, Curtis, Zschäbitz, Stefanie, Oldenburg, Jan, Ye, Dingwei, Lin, Xun, Healy, Cynthia G., Di Santo, Nicola, Laird, A. Douglas, Zohren, Fabian, Agarwal, Neeraj

“…Preclinical evidence has suggested an interplay between the androgen receptor, which largely drives the growth of prostate cancer cells, and poly(ADP-ribose)…”
Get full text

Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy by Templeton, Arnoud J, Knox, Jennifer J, Lin, Xun, Simantov, Ronit, Xie, Wanling, Lawrence, Nicola, Broom, Reuben, Fay, André P, Rini, Brian, Donskov, Frede, Bjarnason, Georg A, Smoragiewicz, Martin, Kollmannsberger, Christian, Kanesvaran, Ravindran, Alimohamed, Nimira, Hermanns, Thomas, Wells, J. Connor, Amir, Eitan, Choueiri, Toni K, Heng, Daniel Y.C

“…Abstract Background Neutrophil-to-lymphocyte ratio (NLR), if elevated, is associated with worse outcomes in several malignancies. Objective Investigation of…”
Get full text

Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma by Callea, Marcella, Albiges, Laurence, Gupta, Mamta, Cheng, Su-Chun, Genega, Elizabeth M, Fay, André P, Song, Jiaxi, Carvo, Ingrid, Bhatt, Rupal S, Atkins, Michael B, Hodi, F Stephen, Choueiri, Toni K, McDermott, David F, Freeman, Gordon J, Signoretti, Sabina

“…PD-L1 expression in primary clear-cell renal cell carcinoma (ccRCC) increases the likelihood of response to anti-PD-1 inhibition, but fails to identify all…”
Get more information

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study by Azad, Arun A., Fizazi, Karim, Matsubara, Nobuaki, Saad, Fred, De Giorgi, Ugo, Joung, Jae Young, Fong, Peter C.C., Jones, Robert J., Zschäbitz, Stefanie, Oldenburg, Jan, Shore, Neal D., Dunshee, Curtis, Carles, Joan, Fay, Andre P., Lin, Xun, DeAnnuntis, Liza, Di Santo, Nicola, Zielinski, Michael A., Agarwal, Neeraj

“…This detailed analysis further characterizes the safety profile of talazoparib plus enzalutamide in the ongoing randomized, phase III TALAPRO-2 study in…”
Get full text

Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma by Albiges, Laurence, Fay, André P, Xie, Wanling, Krajewski, Katherine, McDermott, David F, Heng, Daniel Y.C, Dariane, Charles, DeVelasco, Guillermo, Lester, Renee, Escudier, Bernard, Choueiri, Toni K

“…Highlights • The efficacy of targeted therapy (TT) after PD-1/ PD-L1 blockade is unknown in mRCC. • We conducted a retrospective analysis of mRCC patients…”
Get full text

Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma by Loriot, Yohann, Sternberg, Cora N., Castellano, Daniel, Oosting, Sjoukje F., Dumez, Herlinde, Huddart, Robert, Vianna, Karina, Alonso Gordoa, Teresa, Skoneczna, Iwona, Fay, Andre P., Nolè, Franco, Massari, Francesco, Brasiuniene, Birute, Maroto, Pablo, Fear, Simon, Di Nucci, Flavia, de Ducla, Sabine, Choy, Ernest

“…Patients with pre-existing autoimmune disease (AID) are typically excluded from clinical trials of immune checkpoint inhibitors, and there are limited data on…”
Get full text

Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials by Moreira, Raphael B, Debiasi, Marcio, Francini, Edoardo, Nuzzo, Pier V, Velasco, Guillermo De, Maluf, Fernando C, Fay, Andre P, Bellmunt, Joaquim, Choueiri, Toni K, Schutz, Fabio A

“…Abiraterone and enzalutamide are currently approved for mCRPC patients. Both drugs have distinct mechanisms of action and may have different toxicity profile…”
Get full text

ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis by Urun, Yuksel, Leow, Jeffrey J., Fay, Andre P., Albiges, Laurence, Choueiri, Toni K., Bellmunt, Joaquim

“…The predictive role of excision repair cross-complementing group 1 (ERCC1) as a predictive factor in patients with advanced urothelial cancer (AUC) treated…”
Get full text

Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial by Fizazi, Karim, Azad, Arun A., Matsubara, Nobuaki, Carles, Joan, Fay, Andre P., De Giorgi, Ugo, Joung, Jae Young, Fong, Peter C. C., Voog, Eric, Jones, Robert J., Shore, Neal D., Dunshee, Curtis, Zschäbitz, Stefanie, Oldenburg, Jan, Ye, Dingwei, Lin, Xun, Healy, Cynthia G., Di Santo, Nicola, Laird, A. Douglas, Zohren, Fabian, Agarwal, Neeraj

Get full text

Molecular characterization of metastatic penile squamous cell carcinoma in developing countries and its impact on clinical outcomes: LACOG 2018 translational study by Monteiro, Fernando Sabino Marques, Alencar Junior, Antonio Machado, da Trindade, Karine Martins, Rebelatto, Taiane Francieli, Maluf, Fernando C, Gazzola, Antonia A, Barrios, Pablo M, Bellmunt, Joaquim, de Jesus, Rafaela Gomes, Silva, Gyl Eanes Barros, Teixeira Junior, Antonio Augusto Lima, Spiess, Philippe E, Fay, Andre P

“…Penile squamous cell carcinoma (PSCC) is a rare malignancy. However, in developing countries the incidence rate is higher. The understanding of molecular…”
Get full text

Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation by Baca, Sylvan C., Singler, Cassandra, Zacharia, Soumya, Seo, Ji-Heui, Morova, Tunc, Hach, Faraz, Ding, Yi, Schwarz, Tommer, Huang, Chia-Chi Flora, Anderson, Jacob, Fay, André P., Kalita, Cynthia, Groha, Stefan, Pomerantz, Mark M., Wang, Victoria, Linder, Simon, Sweeney, Christopher J., Zwart, Wilbert, Lack, Nathan A., Pasaniuc, Bogdan, Takeda, David Y., Gusev, Alexander, Freedman, Matthew L.

“…Many genetic variants affect disease risk by altering context-dependent gene regulation. Such variants are difficult to study mechanistically using current…”
Get full text

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma by McKay, Rana R, Bossé, Dominick, Xie, Wanling, Wankowicz, Stephanie A M, Flaifel, Abdallah, Brandao, Raphael, Lalani, Aly-Khan A, Martini, Dylan J, Wei, Xiao X, Braun, David A, Van Allen, Eliezer, Castellano, Daniel, De Velasco, Guillermo, Wells, J Connor, Heng, Daniel Y, Fay, Andre P, Schutz, Fabio A, Hsu, JoAnn, Pal, Sumanta K, Lee, Jae Lyun, Hsieh, James J, Harshman, Lauren C, Signoretti, Sabina, Motzer, Robert J, Feldman, Darren, Choueiri, Toni K

“…Programmed death 1 (PD-1) and PD ligand 1 (PD-L1) inhibitors have shown activity in metastatic clear cell renal cell carcinoma (ccRCC). Data on the activity of…”
Get more information

Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model by de Velasco, Guillermo, Culhane, Aedín C., Fay, André P., Hakimi, A. Ari, Voss, Martin H., Tannir, Nizar M., Tamboli, Pheroze, Appleman, Leonard J., Bellmunt, Joaquim, Kimryn Rathmell, W., Albiges, Laurence, Hsieh, James J., Heng, Daniel Y. C., Signoretti, Sabina, Choueiri, Toni K.

“…Introduction Gene‐expression signatures for prognosis have been reported in localized renal cell carcinoma (RCC). The aim of this study was to test the…”
Get full text